191 related articles for article (PubMed ID: 22392572)
1. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Reardon DA; Conrad CA; Cloughesy T; Prados MD; Friedman HS; Aldape KD; Mischel P; Xia J; DiLea C; Huang J; Mietlowski W; Dugan M; Chen W; Yung WK
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1507-18. PubMed ID: 22392572
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
Reardon DA; Cloughesy T; Rich J; Alfred Yung WK; Yung L; DiLea C; Huang J; Dugan M; Mietlowski W; Maes A; Conrad C
Cancer Chemother Pharmacol; 2012 Jan; 69(1):281-7. PubMed ID: 21984222
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
4. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
Baselga J; Mita AC; Schöffski P; Dumez H; Rojo F; Tabernero J; DiLea C; Mietlowski W; Low C; Huang J; Dugan M; Parker K; Walk E; van Oosterom A; Martinelli E; Takimoto CH
Clin Cancer Res; 2012 Nov; 18(22):6364-72. PubMed ID: 23014528
[TBL] [Abstract][Full Text] [Related]
5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
6. The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats.
Deng M; Huang H; Jin H; Dirsch O; Dahmen U
Invest New Drugs; 2011 Aug; 29(4):593-606. PubMed ID: 20148349
[TBL] [Abstract][Full Text] [Related]
7. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
8. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
9. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
[TBL] [Abstract][Full Text] [Related]
12. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
[TBL] [Abstract][Full Text] [Related]
15. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Chheda MG; Wen PY; Hochberg FH; Chi AS; Drappatz J; Eichler AF; Yang D; Beroukhim R; Norden AD; Gerstner ER; Betensky RA; Batchelor TT
J Neurooncol; 2015 Feb; 121(3):627-34. PubMed ID: 25503302
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Holden SN; Eckhardt SG; Basser R; de Boer R; Rischin D; Green M; Rosenthal MA; Wheeler C; Barge A; Hurwitz HI
Ann Oncol; 2005 Aug; 16(8):1391-7. PubMed ID: 15905307
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Schiff D; Kesari S; de Groot J; Mikkelsen T; Drappatz J; Coyle T; Fichtel L; Silver B; Walters I; Reardon D
Invest New Drugs; 2015 Feb; 33(1):247-53. PubMed ID: 25388940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
